Correction: A proteomic analysis of individual and gender variations in normal human urine and cerebrospinal fluid using iTRAQ quantification (PLoSONE (2019)10:7 (e0133270) DOI: 10.1371/journal.pone.0133270);A proteomic analysis of individual and gender variations in normal human urine and cerebrospinal fluid using iTRAQ quantification

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Guo, Zhengguang ^a   Zhang, Yang ^b   Zou, Lili ^a   Wang, Danqi ^a   Shao, Chen ^a   Wang, Yajie ^b   Sun, Wei ^a   Zhang, Liwei ^b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

ADULT; ANALYTIC METHOD; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOBARIC TAG FOR THE RELATIVE AND ABSOLUTE QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SECRETION; PROTEIN URINE LEVEL; PROTEOMICS; QUANTITATIVE ANALYSIS; SAMPLE SIZE; SEX DIFFERENCE; URINALYSIS; CHEMISTRY; COMPARATIVE STUDY; GENE ONTOLOGY; ISOTOPE LABELING; METABOLISM; PROCEDURES; SEX FACTOR; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; URINE; YOUNG ADULT;

ADULT; CEREBROSPINAL FLUID PROTEINS; CHROMATOGRAPHY, LIQUID; FEMALE; GENE ONTOLOGY; HUMANS; ISOTOPE LABELING; MALE; PROTEOME; PROTEOMICS; SEX FACTORS; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY; URINALYSIS; URINE; YOUNG ADULT;

EID: 84941710827     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0213213     Document Type: Erratum

References (23)

1. Liu X, Shao C, Wei L, Duan J, Wu S, Li X, et al. An individual urinary proteome analysis in normal human beings to define the minimal sample number to represent the normal urinary proteome. Proteome Sci. 2012; 10: 70. doi: 10.1186/1477-5956-10-70 PMID: 23170922
2. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands JL, et al. Urine in clinical proteomics. Mol Cell Proteomics. 2008; 7: 1850-1862. doi: 10.1074/mcp.R800001-MCP200 PMID: 18667409
3. Yang N, Feng S, Shedden K, Xie X, Liu Y, Rosser CJ, et al. Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res. 2011; 17: 3349-3359. doi: 10.1158/1078-0432.CCR-10-3121 PMID: 21459797
4. Vivekanandan-Giri A, Slocum JL, Buller CL, Basrur V, JuW, Pop-Busui R, et al. Urine glycoprotein profile reveals novel markers for chronic kidney disease. Int J Proteomics. 2011; 2011: 214715. doi: 10.1155/2011/214715 PMID: 22091387
5. Lim SC, Liying DQ, Toy WC, Wong M, Yeoh LY, Tan C, et al. Adipocytokine zinc alpha2 glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Diabet Med. 2012; 29: 945-949. doi: 10.1111/j.1464-5491.2011.03564.x PMID: 22211921
6. Choi YS, Hou S, Choe LH, Lee KH Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 930: 129-135. doi: 10.1016/j.jchromb.2013.05.003 PMID: 23735279
7. Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, et al. Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. J Alzheimers Dis. 2012; 28: 625-636. doi: 10.3233/JAD-2011-111505 PMID: 22045497
8. Lehnert S, Jesse S, Rist W, Steinacker P, Soininen H, Herukka SK, et al. iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp Neurol. 2012; 234: 499-505. doi: 10.1016/j.expneurol.2012.01.024 PMID: 22327139
9. Rajagopal MU, Hathout Y, MacDonald TJ, Kieran MW, Gururangan S, Blaney SM, et al. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011; 11: 935-943. doi: 10.1002/pmic.201000198 PMID: 21271676
10. Thongboonkerd V, Chutipongtanate S, Kanlaya R Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: Quantity, quality, and variability. J Proteome Res. 2006; 5: 183-191. PMID: 16396510
11. Nagaraj N, Mann M Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome. J Proteome Res. 2011; 10: 637-645. doi: 10.1021/pr100835s PMID: 21126025
12. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM Comparative proteomic analysis of intraand interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics. 2005; 4: 2000-2009. PMID: 16199891
13. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L, et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics. 2010; 9: 2063-2075. doi: 10.1074/mcp.M900877-MCP200 PMID: 20811074
14. Schutzer SE, Liu T, Natelson BH, Angel TE, Schepmoes AA, Purvine SO, et al. Establishing the proteome of normal human cerebrospinal fluid. PLoS One. 2010; 5: E10980. doi: 10.1371/journal.pone. 0010980 PMID: 20552007
15. Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C, et al. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: Assessment of technical and inter-individual variation. PLoS One. 2013; 8: E64314. doi: 10.1371/journal.pone.0064314 PMID: 23700471
16. Wisniewski JR, Zougman A, Nagaraj N, Mann M Universal sample preparation method for proteome analysis. Nat Methods. 2009; 6: 359-362. doi: 10.1038/nmeth.1322 PMID: 19377485
17. Jia L, Li X, Shao C, Wei L, Li M, Guo Z, et al. Using an isolated rat kidney model to identify kidney origin proteins in urine. PLoS One. 2013; 8: E66911. doi: 10.1371/journal.pone.0066911 PMID: 23825584
18. Havanapan PO, Thongboonkerd V Are protease inhibitors required for gel-based proteomics of kidney and urine? J Proteome Res. 2009; 8: 3109-3117. doi: 10.1021/pr900015q PMID: 19354301
19. Park SK, Venable JD, Xu T, Yates JR 3rd A quantitative analysis software tool for mass spectrometrybased proteomics. Nat Methods. 2008; 5: 319-322. doi: 10.1038/nmeth.1195 PMID: 18345006
20. Higgs RE, Butler JP, Han B, Knierman MD Quantitative Proteomics via High Resolution MS Quantification: Capabilities and Limitations. Int J Proteomics. 2013; 2013: 674282. doi: 10.1155/2013/674282 PMID: 23710359
21. Karp NA, Huber W, Sadowski PG, Charles PD, Hester SV, Lilley KS Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics. 2010; 9: 1885-1897. doi: 10.1074/mcp. M900628-MCP200 PMID: 20382981
22. Mertins P, Udeshi ND, Clauser KR, Mani DR, Patel J, Ong SE, et al. iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012; 11: M111 014423.
23. Rodriguez-Rodriguez A, Egea-Guerrero JJ, Leon-Justel A, Gordillo-Escobar E, Revuelto-Rey J, Vilches-Arenas A, et al. Role of S100B protein in urine and serum as an early predictor of mortality after severe traumatic brain injury in adults. Clin Chim Acta. 2012; 414: 228-233. doi: 10.1016/j.cca.2012. 09.025 PMID: 23031665